Home
Products
DrugLnk Products
ADC Toxins
AZD8055, Free Base

AZD8055, Free Base (CAT#: ADC-P-064)

ADCs Toxins, AZD8055 is a ATP-competitive and selective inhibitor of mammalian target of rapamycin kinase with an IC50 value of 0.8 nM.

Product Information

Description
ADCs Toxins, AZD8055 is a ATP-competitive and selective inhibitor of mammalian target of rapamycin kinase with an IC50 value of 0.8 nM.

Classification
Others

Molecular Weight
465.54

Purity
95%

For Research Use Only. NOT FOR CLINICAL USE.

Published Data

+ Submit Publications

Submit a review or a question

Scientific Resources

CAMouse™-Fully Human Antibody Generation Platform

Reviews

Literature

Protocol

Customer Reviews and FAQs

There are currently no Customer reviews or questions for ADC-P-064. Click the button above to contact us or submit your feedback about this product.

Customer Reviews FAQ

Excellent

AZD8055 from Creative Biolabs has proven to be a valuable tool in my mTOR pathway research. Its ability to inhibit both mTORC1 and mTORC2 made it essential for studying cancer cell signaling in my experiments.

Excellent

This inhibitor has been particularly effective in my work targeting tumor growth. AZD8055 showed clear suppression of cell proliferation, providing useful insights into mTOR-related therapeutic strategies.

Excellent

This product greatly supported my drug resistance research. AZD8055 was effective in sensitizing cancer cells to other therapies, making it a critical component in combination treatment experiments.

Excellent

I used AZD8055 in cell cycle studies, and it provided clear evidence of mTOR pathway involvement in cell division. The inhibitor was key to observing arrest in cancer cell lines during the S phase.

Excellent

AZD8055 has been a pivotal asset in my ADC research, particularly in examining the mTOR pathway's role in drug resistance. The inhibitor's effectiveness in reducing mTOR activity provided valuable insights into improving ADC efficacy and overcoming resistance mechanisms.

Q: 1: How does AZD8055 function in ADC development?
A: AZD8055 can be integrated into ADCs to enhance their efficacy by inhibiting mTOR pathways in cancer cells, leading to reduced proliferation and increased sensitivity to cytotoxic agents.
Q: 2: What types of cancer can AZD8055, Free Base, target?
A: AZD8055, Free Base, is effective against a wide range of cancers, including breast, prostate, and lung cancers, by inhibiting mTOR signaling critical for tumor growth and survival.
Q: 3: How does AZD8055 affect mTOR signaling in cancer cells?
A: AZD8055 blocks mTORC1 and mTORC2 activity, leading to reduced protein synthesis, inhibition of cell growth, and induction of apoptosis in cancer cells, making it a potent therapeutic agent.
Q: 4: Can AZD8055 be combined with other drugs in ADCs?
A: Yes, AZD8055 can be combined with other cytotoxic agents in ADCs to enhance their anticancer effects, particularly in targeting mTOR-dependent cancer cells and overcoming drug resistance.
Q: 5: What are the key challenges of using AZD8055 in ADC development?
A: The main challenges include optimizing its release mechanism in the tumor microenvironment and managing potential off-target effects due to its potent mTOR inhibition.

Quick Links

ADC Toxins

Drug-linker Complexes

Customized ADCs

Anti-Ab ADCs

Online Inquiry

Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.